KL1333

Phase 2Small molecule

AAbliva AB

KL1333 is one of 11 small molecule programs targeting Mitochondrial Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mitochondrial DiseaseRecruiting

Mitochondrial DiseasePhase 2

Recruiting

Competition

Competitive Landscape

17 competitors in Mitochondrial Disease

#DrugCompanyPhaseTrials

Firazyr

Depakote

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—4

Forzinity

SStealth BioTherapeutics Inc.

Phase 3

2 5

Procysbi

HHorizon Therapeutics Ireland DAC

Phase 2

2 6

Vatiquinone

PPTC Therapeutics

Phase 3

2 7

Coenzymeq10

TTanta University

Phase 3

1 8

Sonlicromanol

KKhondrion BV

Phase 3

—9

OMT-28

OOmeicos Therapeutics GmbH

Phase 2

1 10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Mitochondrial Disease

NCT05650229

Clinical

Trials by Indication[1]

Mitochondrial Disease2 trials

A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease

Completed·AAbliva AB·Phase 1·NCT03888716·72 enrolled

An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose, Adaptive Study of the Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

Recruiting·AAbliva AB·Phase 2·NCT05650229·180 enrolled

Interaction1 trial

Drug-drug Interaction Study of KL1333 in Healthy Subjects

Completed·AAbliva AB·Phase 1·NCT04643249·14 enrolled

Unspecified1 trial

Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers

Completed·YYungjin Pharm. Co., Ltd.·Phase 1·NCT03056209·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for KL1333. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KL1333 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KL1333. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Abliva AB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAbliva AB

KL1333

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Mitochondrial Disease2 trials

Interaction1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News